What is the minimum investment required for PCD Pharma Franchise?

The minimum investment typically ranges from ₹2–5 lakhs, depending on territory size, product selection and initial stock planning. Our team will help structure this based on your goals.

What documents are required to become a franchise partner?

You will need a valid Drug License, GST registration and basic KYC documents. Our team will guide you through every step of the documentation process.

What kind of support and training do you provide?

We provide product training, sales guidance, marketing materials, doctor coverage strategies, and ongoing business support through dedicated account managers.

How are territories allocated and protected?

Territories are allocated based on mutual agreement and market mapping. We offer genuine monopoly rights with clear documentation to avoid internal competition.

What is the expected profit margin and ROI timeline?

Average profit margins range from 25–30%, with typical ROI timelines between 12–18 months, depending on your execution and territory potential.

How do you ensure product quality and compliance?

All products are manufactured in WHO-GMP certified facilities with 100% quality testing, robust documentation and DCGI approvals as applicable.

What is the delivery timeline and process?

Dispatch timelines depend on order size and location, but we maintain a strong track record of timely delivery across India with proper packaging and logistics partners.

Vials

Zami-100

Amikacin-100mg Inj

Pack: SINGLE
Format: With Carton

MRP₹16.70

A potent aminoglycoside antibiotic injection formulated for the targeted treatment of serious bacterial infections. ZAMI-100 contains Amikacin 100mg, a broad-spectrum antimicrobial agent engineered to eliminate resistant Gram-negative pathogens and manage complex systemic infections.

About The Product

Key Benefits

Broad-Spectrum Bactericidal Action

Amikacin 100mg works by binding to the bacterial 30S ribosomal subunit, causing the misreading of genetic code and inhibiting protein synthesis. This lead to the rapid destruction of the bacterial cell wall and the death of the pathogen.

Resistance to Modifying Enzymes

As a semi-synthetic aminoglycoside, Amikacin is uniquely designed to resist degradation by most aminoglycoside-inactivating enzymes. This makes it highly effective against bacterial strains that have developed resistance to other antibiotics like Gentamicin or Tobramycin.

Rapid Systemic Distribution

The injectable delivery system ensures immediate therapeutic concentrations in the plasma and extracellular fluids. It demonstrates excellent penetration into the lungs, bones, and soft tissues, making it a reliable choice for acute clinical management.

Targeteddd Gram-Negative Coverage

The formulation is exceptionally potent against aerobic Gram-negative bacteria, including Pseudomonas aeruginosa, Escherichia coli, and Klebsiella species, which are often implicated in hospital-acquired infections.

Synergistic Clinical Efficacy

In severe clinical scenarios, Amikacin can be used in combination with beta-lactam antibiotics to provide an expanded spectrum of coverage, ensuring the successful management of mixed or unknown bacterial etiologies.

Precision Pediatric and Adult Dosing

The 100mg strength allows for precise dose calculation and administration, particularly in pediatric care or for localized infections where a controlled, lower-concentration dose is required to minimize the risk of ototoxicity or nephrotoxicity.

Indication Neonatal Sepsis, Complicated Urinary Tract Infections (UTI), Severe Respiratory Tract Infections, Bone and Joint Infections, Intra-abdominal Infections, Post-Surgical Prophylaxis.

Indications

Neonatal Sepsis
Complicated Urinary Tract Infections (UTI)
Severe Respiratory Tract Infections
Bone and Joint Infections
Intra-abdominal Infections
Post-Surgical Prophylaxis.

Product descriptions, dosage forms, and compositions listed on the website are for reference by licensed practitioners and distributors only.

Zami-100